Shanghai Yudan Pharmaceutical

Shanghai Yudan Pharmaceutical is a clinical-stage biotechnology company based in Shanghai, China, specializing in the discovery and development of innovative treatments for dermatological and inflammatory diseases. The company focuses on developing highly selective small molecule inhibitors, with a primary emphasis on topical applications to minimize systemic side effects. Its lead candidate, YD-01, is a potent phosphodiesterase 4 (PDE4) inhibitor currently undergoing clinical evaluation for the treatment of plaque psoriasis and atopic dermatitis. By leveraging a proprietary medicinal chemistry platform, Shanghai Yudan aims to address the significant unmet medical needs of patients suffering from chronic skin conditions. The company is backed by prominent venture capital firms and continues to expand its pipeline into broader immunological indications.